InspireMD Announces Stock Exchange Listing Transfer to Nasdaq
11 May 2021 - 6:05AM
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™
Embolic Prevention System (EPS) for the prevention of stroke caused
by the treatment of Carotid Artery Disease (CAD), today announced
the Company’s shares have been approved for listing on The Nasdaq
Capital Market (“Nasdaq”). Trading is expected to begin on May
21, 2021, under the symbol NSPR on the Nasdaq.
InspireMD CEO Marvin Slosman commented, “We believe that moving
to the Nasdaq Capital Market is a strategically important change
that places us in the company of our peers and allows us greater
access to a wider set of investors, thereby enabling us to build
our fundamental base of investors. InspireMD is a stronger company
today than ever before, and I am proud of the extraordinary efforts
of our expanding team in creating an exciting future for our
company. We are extremely pleased to now be a part of the Nasdaq
exchange and value our new relationship.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology
to make its products the industry standard for carotid stenting by
providing outstanding acute results and durable, stroke-free,
long-term outcomes.
As of May 21, 2021, InspireMD’s common stock will be quoted on
the Nasdaq under the ticker symbol NSPR.
Forward-looking Statements
This press release contains “forward-looking
statements.” Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are not
guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company’s control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks and uncertainties associated with (i)
market acceptance of our existing and new products, (ii) negative
clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of
our products, (iv) intense competition in the medical device
industry from much larger, multinational companies, (v) product
liability claims, (vi) product malfunctions, (vii) our limited
manufacturing capabilities and reliance on subcontractors for
assistance, (viii) insufficient or inadequate reimbursement by
governmental and other third party payers for our products, (ix)
our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be
successful, (x) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (xi) our
reliance on single suppliers for certain product components, (xii)
the fact that we will need to raise additional capital to meet our
business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xiii) the fact
that we conduct business in multiple foreign jurisdictions,
exposing us to foreign currency exchange rate fluctuations,
logistical and communications challenges, burdens and costs of
compliance with foreign laws and political and economic instability
in each jurisdiction. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Investor Contacts:
Craig ShoreChief Financial OfficerInspireMD,
Inc.888-776-6804craigs@inspiremd.com
CORE IRinvestor-relations@inspiremd.com
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Dec 2024 to Jan 2025
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Jan 2024 to Jan 2025